RNS Number : 6811C
N4 Pharma PLC
19 June 2019

19 June 2019

N4 Pharma Plc
("**N4 Pharma**" or the "**Company**")

AGM statement

N4 Pharma Plc (AIM: N4P), the specialist pharmaceutical company developing Nuvec®, a novel delivery system for vaccines and cancer treatments, announces that at its annual general meeting, being held later today, Nigel Theobald, Chief Executive Officer, will provide the following update on the timings for the recently announced repeat of the *in vivo* work at University of Queensland ("UQ").

As previously announced, studies to date have demonstrated that Nuvec® consistently promotes transfection in *in vitro* experiments using both DNA and messenger RNA (mRNA) plasmids. The primary *in vivo* study conducted by UQ also demonstrated that Nuvec® is effective *in vivo*, as a measurable antibody response was achieved using Ovalbumin plasmid DNA (OVA pDNA).

Evaluation of subsequent *in vivo* studies conducted by other laboratories indicated that the preparation and loading of Nuvec® with DNA or mRNA differed to the methods used by UQ in the primary study. By returning to UQ to repeat the successful *in vivo* work using OVA pDNA, the Company expects to affirm the precise loading protocol and methodology and to properly document the process for successful technology transfer to other CROs and partners. This will provide the benchmark conditions to be used to evaluate the delivery of antigen by Nuvec® in a well characterised oncology efficacy model.

The relevant committees at UQ have now approved the commencement of the studies and, with this approval, the experiments are expected to start on 21 June 2019. UQ has advised that results are expected to be available in approximately two months. The repeat work at UQ will be monitored and recorded by N4's Head of CMC Programme Development, Dr Allan Hey.

The Board is pleased to now have greater clarity on the timing of the next UQ work and believe a properly documented protocol, by repeating the earlier successful study, will enable the Company to accelerate other studies. The Company remains well funded to achieve this objective.

The Directors of the Company are mindful that Nuvec® will not work first time for every application and in every experiment. There are many variables to consider in any pre-clinical experiment, such as the antigen itself, how to load it onto Nuvec®, the dose, concentration of Nuvec® and injection volume and understanding how these factors can cause inconsistency is an important part of Nuvec®'s development. The Directors remain confident that Nuvec® has the potential to be an innovative and effective delivery system in the field of nucleic acid vaccines and therapeutics."

Enquiries:

N4 Pharma Plc
Nigel Theobald, CEO — Via Scott PR

Allenby Capital Limited
James Reeve/Asha Chotai — Tel: +44 (0)203 328 5656

Scott PR
Georgia Smith — Tel: +44 (0)1477 539 539

About N4 Pharma
N4 Pharma is a specialist pharmaceutical company developing a novel delivery system for vaccines and cancer treatments using its unique silica nanoparticle delivery system called Nuvec®.

N4 Pharma's business model is to partner with companies developing novel antigens for vaccines and cancer treatments to use Nuvec® as the delivery vehicle to get their antigen into cells to express the protein needed for the required immunity. As these products progress through pre clinical and clinical programs, N4 Pharma will seek to receive up front payments, milestone payments and ultimately royalty payments once products reach the market.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

END

AGMBCGDLGXBBGCI